BA
BMRN icon

Bridgewater Associates’s BioMarin Pharmaceuticals BMRN Stock Holding History

Bridgewater Associates’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$15.7M Buy
274,911
+68,000
+33% +$3.72M 0.06% 252
2026
Q1 		$11.7M Sell
206,911
-23,050
-10% -$1.34M 0.05% 243
2025
Q4 		$13.7M Sell
229,961
-145,722
-39% -$7.93M 0.05% 276
2025
Q3 		$20.3M Buy
375,683
+147,937
+65% +$8.46M 0.08% 196
2025
Q2 		$12.5M Buy
227,746
+104,090
+84% +$6.13M 0.05% 231
2025
Q1 		$8.74M Sell
123,656
-178,824
-59% -$12M 0.04% 281
2024
Q4 		$19.9M Buy
302,480
+160,166
+113% +$10.7M 0.09% 168
2024
Q3 		$10M Buy
142,314
+107,330
+307% +$8.97M 0.06% 262
2024
Q2 		$2.88M Buy
34,984
+31,618
+939% +$2.63M 0.02% 465
2024
Q1 		$294K Sell
3,366
-187,604
-98% -$16.8M ﹤0.01% 657
2023
Q4 		$18.4M Buy
190,970
+29,576
+18% +$2.62M 0.1% 152
2023
Q3 		$14.3M Buy
161,394
+11,418
+8% +$1.02M 0.09% 177
2023
Q2 		$13M Buy
149,976
+25,932
+21% +$2.44M 0.08% 170
2023
Q1 		$12.1M Buy
124,044
+17,665
+17% +$1.83M 0.07% 184
2022
Q4 		$11M Sell
106,379
-1,165
-1% -$109K 0.06% 239
2022
Q3 		$9.12M Buy
107,544
+67,829
+171% +$6.04M 0.05% 266
2022
Q2 		$3.29M Buy
39,715
+20,065
+102% +$1.6M 0.01% 592
2022
Q1 		$1.51M Buy
19,650
+5,667
+41% +$474K 0.01% 736
2021
Q4 		$1.24M Sell
13,983
-27
-0.2% -$2.23K 0.01% 536
2021
Q3 		$1.08M Sell
14,010
-9,171
-40% -$724K 0.01% 503
2021
Q2 		$1.93M Buy
23,181
+9,743
+73% +$772K 0.01% 494
2021
Q1 		$1.01M Buy
+13,438
New +$1.1M 0.01% 313
2016
Q4 		– Sell
-8,926
Closed -$826K – 284
2016
Q3 		$826K Buy
+8,926
New +$841K 0.01% 234
2014
Q2 		– Sell
-48,400
Closed -$3.3M – 319
2014
Q1 		$3.3M Buy
+48,400
New +$3.57M 0.03% 148

Other funds holding BMRN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Bridgewater Associates's BMRN Position: Q2 2026 in Review

Bridgewater Associates increased its BioMarin Pharmaceuticals (BMRN) stake by 33% in Q2 2026, buying an estimated $3.72M and bringing the position to 274,911 shares worth $15.7M. The position accounts for 0.06% of the portfolio, ranked #252.

Bridgewater Associates first reported a position in BMRN in Q1 2014 and has held it in 24 quarters since. The position peaked at $20.3M in Q3 2025. 565 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

  • Bridgewater Associates held 274,911 shares of BioMarin Pharmaceuticals worth $15.7M as of Q2 2026.
  • Bridgewater Associates bought 68,000 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $3.72M.
  • BioMarin Pharmaceuticals made up 0.06% of Bridgewater Associates's portfolio in Q2 2026, its #252 holding.
  • Bridgewater Associates first reported a position in BioMarin Pharmaceuticals in Q1 2014 and has held it in 24 quarters since.
  • Bridgewater Associates's BioMarin Pharmaceuticals position peaked at $20.3M in Q3 2025.
  • 565 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Bridgewater Associates's 13F filing for Q2 2026, filed 14 Aug 2026.